RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 1999; 82(01): 145-148
DOI: 10.1055/s-0037-1614644
DOI: 10.1055/s-0037-1614644
Scientific and Standardization Committee Communication
A Soluble Fibrin Standard: Comparable Dose-response with Immunologic and Functional Assays[*]
This work was supported in part by Grants HL-07152 and HL-30616 from the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Weitere Informationen
Publikationsverlauf
Received
14. Januar 1998
Accepted after resubmission
19. Februar 1999
Publikationsdatum:
11. Dezember 2017 (online)
Summary
A soluble fibrin (SF) preparation has been developed as a potential standard by the Scientific and Standardization Committee for use in assays evaluating in vitro preparations and patient plasma samples. The SF standard was prepared by reaction of factor XIII-free fibrinogen with thrombin, followed by neutralization with hirudin and solubilization of the fibrin in acetic acid. As characterized by SDS-PAGE, the polypeptide chain structure shows the anticipated loss of fibrinopep-tides and lack of sγ or α chain crosslinking. The standard was added to pooled normal plasma at concentrations from 12.5 μg/ml to 340 μg/ml and tested with four commercially available assays based on immunologic reactions using ELISA or latex agglutination or on t-PA cofactor activity for plasminogen to plasmin conversion. Absolute “soluble fibrin” concentrations were calculated using the manufacturers’ calibrators and showed distinct dose-response relationships for each assay. Expression of the results following log-transformation produced a series of parallel lines, indicating that this SF preparation can serve as a standard, effectively normalizing the disparate proprietary internal calibrators currently used for each assay.
* Report prepared on behalf of the DIC Subcommittee of the SSC
-
References
- 1 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53.
- 2 Lane DA, Ireland H. Wolff S, Grant R, Jennings S, Allen-Mersh T. Plasma concentrations of fibrinopeptide A, fibrinogen fragment Bβ1-42. and β-thromboglobulin following total hip replacement. Thromb Res 1982; 26: 111-8.
- 3 Amiral J, Walenga JM, Fareed J. Development and peformance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Sem Thromb Hemost 1984; 10: 228-42.
- 4 Francis CW, Connaghan DG, Scott WL, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation 1987; 75: 1170-7.
- 5 Kornberg A, Francis CW, Marder VJ. Plasma crosslinked fibrin polymers: Quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normals and patients with acute thrombotic disorders. Blood 1992; 80: 709-17.
- 6 Lill H, Spannagl M, Trauner A, Schramm W, Schuller D, Ofenloch-Haehnle B, Draeger B, Naser W, Dessauer A. A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo. Blood Coag Fibrinoly 1993; 4: 97-102.
- 7 Schielen WJG, Adams HPHM, van Leuven K, Voskuilen M, Tesser I G, Nieuwenhuizen W. The sequence γ-(312-324) is a fibrin-specific epitope. Blood 1991; 77: 2169-73.
- 8 Nieuwenhuizen W, Hoegee-De Nobel E, Laterveer R. A rapid monoclonal antibody-based enzyme immunoassay (EIA) for the quantitative determination of soluble fibrin in plasma. Thromb Haemost 1992; 68: 273-7.
- 9 Soe G, Kohno I, Inuzuka K, Itoh Y, Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexes with fibrinogen or its derivatives: Its application to the measurement of soluble fibrin in plasma. Blood 1996; 88: 2109-17.
- 10 Wiman B, Ranby M. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb Haemost 1986; 55: 189-93.
- 11 van Wersch JWJ. Adaptation and evaluation of a chromogenic test procedure for fibrin monomers on a centrifugal analyzer. J Clin Chem Clin Biochem 1990; 28: 169-74.
- 12 Vogel G, Spanuth E. Predictive value of fibrin monomers in postoperative deep vein thrombosis. Klin Wochenschr 1990; 68: 1020-6.
- 13 Vogel G, Dempfle C-E, Spannagl M, Leskopf W. The value of quantitative fibrin monomer determination in the early diagnosis of postoperative deep vein thrombosis. Thromb Res 1996; 81: 241-51.
- 14 Ginsberg JS, Siragusa S, Douketis J, Johnston M, Moffat K, Stevens P, Brill-Edwards P, Panju A, Patel A. Evaluation of a soluble fibrin assay in patients with suspected deep vein thrombosis. Thromb Haemost 1995; 74: 833-6.
- 15 Ginsberg JS, Siragusa S, Douketis J, Johnston M, Moffat K, Donovan D, McGinnis J, Brill-Edwards P, Panju A, Patel A, Weitz JI. Evaluation of a soluble fibrin assay in patients with suspected pulmonary embolism. Thromb Haemost 1996; 75: 551-4.
- 16 Brimble KS, Ginsberg JS. Evaluation of the combination of a bedside D-dimer assay and enzyme-linked immunosorbent soluble fibrin assay in patients with suspected venous thromboembolism. Thromb Res 1997; 88: 291-7.
- 17 Carville DGM, Dimitrijevic N, Walsh M, Digirolamo T, Brill EM, Drew N, Gargan PE. Thrombus precursor protein (TpP®): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin Chem 1996; 42: 1537-41.
- 18 Lee LV, Eward GA, McKenzie CR, Eisenberg PR. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscl Thromb Vasc Biol 1997; 17: 628-33.
- 19 Bredbacka S, Blomback M, Wiman B, Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesth Scand 1993; 37: 125-30.
- 20 Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Deguchi H, Mori Y, Kaneko T, Deguchi K, Fujii J, Shiku H. Increased plasma-soluble fibrin monomer levels in patients with disseminated intra-vascular coagulation. Am J Hematol 1996; 51: 255-60.
- 21 Bremme K, Blomback M. Hemostatic abnormalities may predict chronic hypertension after preeclampsia. Gynecol Obstet Invest 1996; 41: 20-6.
- 22 Ostlund E, Bremme K, Wiman B. Soluble fibrin in plasma as a sign of activated coagulation in patients with pregnancy complications. Acta Obset Gynecol Scand 1998; 77: 165-9.
- 23 Rahr HB, Danielsen D, Andersen BS, Borris LC, Lassen MR. Poor correlation between soluble fibrin concentrations measured by two commercially available immunoassays. Thromb Res 1996; 81: 607-14.
- 24 Wieding JU, Hosius C. Determination of soluble fibrin: A comparison of four different methods. Thromb Res 1992; 65: 745-56.
- 25 Halvorsen S, Skjonsberg OH, Godal HC. Comparison of methods for detecting soluble fibrin in plasma from patients with venous thromboembolism. Thromb Res 1991; 61: 341-8.
- 26 Friberger P. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1975; 7: 138-45.
- 27 Dempfle CE, Dollman M, Lill H, Puzzovio D, Dessauer A, Heene DL. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin α-chain to fibrin polymerization site “A”: effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN. Blood Coag Fibrinol 1993; 4: 79-86.
- 28 Halvorsen S, Skjonsberg OH, Godal HC. Thrombin treated plasma employed as a standard for determination of soluble fibrin. Thromb Res 1993; 72: 305-13.
- 29 Pfitzner SA, Dempfle C-K, Matsuda M, Heene DL. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A. Thromb Haemost 1997; 78: 1069-78.